Head to head
Collegium Pharmaceutical vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: COLL · TAK
COLL
Collegium Pharmaceutical
21.95+0.07%
1-year price shape — -34% over the period
Quant Rating D · 53/100
vs
TAK
Takeda Pharmaceutical
18.29-0.44%
1-year price shape — +29% over the period
Quant Rating C · 70/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (70); Takeda Pharmaceutical has done best over the past year (+29%); Takeda Pharmaceutical pays the highest dividend yield.
| COLL | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | -- | -- |
| Last price | 21.95 | 18.29 |
| Change today | +0.07% | -0.44% |
| 1-year return | -34.3% | +29.2% |
| Market cap | $680.28M | $58.43B |
| 52-week range | 21.43 – 50.79 | 12.77 – 19.10 |
| Valuation | ||
| P/E (TTM) | 17.28 | -55.42 |
| P/E percentile, own 5-yr range | 64th | 4th |
| P/B | 2.18 | 1.22 |
| Dividend yield | 0.00% | 3.27% |
| Profitability & growth | ||
| EPS (TTM) | 1.73 | -0.31 |
| Net profit (TTM) | $53.63M | $-977.54M |
| Revenue (TTM) | $808.21M | $4.62T |
| Revenue growth (YoY) | +6.3% | +10.2% |
| Gross margin | 60.0% | 65.5% |
| Operating margin | 19.5% | 10.4% |
| Net margin | 5.9% | -3.5% |
| Free cash flow (TTM) | $328.28M | $626.68B |
| Ownership & sentiment | ||
| Institutional ownership | 126.8% | 51.5% |
| Insider activity (12mo) | 19 buy / 30 sell | 22 buy / 28 sell |
| Short interest (% of float) | 18.3% | 0.1% |
| Analyst consensus | 86% buy / 14% hold (7) | 100% buy (1) |
| Analyst price target | $49 (+122%) | $43 (+135%) |
| StockVane view | ||
| StockVane Quant Rating | D (53) | C (70) |
| Company | ||
| Employees | 423 | 47,029 |
| Founded | 2002 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.